Skip to content

Prospective monocenter study on clinical outcomes and safety of Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT) for focal articular cartilage lesions of the knee

Prospective monocenter study on clinical outcomes and safety of Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT) for focal articular cartilage lesions of the knee - IMPACT

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON46367
Enrollment
50
Registered
2018-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cartilage defect/ cartilage lesion

Interventions

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Provides written informed consent, is able to understand the content of the study, understands the requirements for follow-up visits and is willing to provide the required information at follow-up visits and in the questionnaires. - Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea). - Age >18 and <45 years old;- Modified Outerbridge Grade III or IV isolated cartilage lesion of the knee. - A post-debridement size of the cartilage lesion > 2cm2 and * 8 cm2 - At least 50% of functional meniscus remaining. Meniscal repair or resection is allowed during the IMPACT surgery provided that the surgeon is able to confirm that at least 50% of functional meniscus remains. - Stable knee ligaments (i.e. anterior and posterior cruciate ligaments).

Exclusion criteria

Exclusion criteria: - Malalignment of >5 degrees - (History of) osteoarthritis, defined as Kellgren-Lawrence grade >3 as determined from appropriate X-ray. - Concomitant inflammatory disease that affects the joint (rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis) - (History of) Septic arthritis. - (History of) Total menisectomy in the target knee joint. - Any surgery in the knee joint 6 months prior to study inclusion. - Risk groups for MRI scanning due to the magnetic field like patients with pacemakers, nerve stimulators, metal particles, stents, clips or implants, (possible) pregnancy or breast feeding.

Design outcomes

Primary

MeasureTime frame
The primary objective is to measure the level of clinical improvement and quality of life at 6, 12 and 18 months. This is assessed by, subscales of, the KOOS and the EQ5D, respectively.

Secondary

MeasureTime frame
The secondary objective is to measure functional repair using MRI at 6 and 18 months postoperative.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)